PALLESCHI, MICHELA
 Distribuzione geografica
Continente #
NA - Nord America 245
AS - Asia 222
EU - Europa 209
AF - Africa 25
Totale 701
Nazione #
US - Stati Uniti d'America 245
SG - Singapore 147
IT - Italia 86
CN - Cina 55
FI - Finlandia 30
DE - Germania 26
CI - Costa d'Avorio 23
SE - Svezia 21
NL - Olanda 12
ID - Indonesia 11
IE - Irlanda 11
CH - Svizzera 5
GB - Regno Unito 5
RU - Federazione Russa 4
BG - Bulgaria 3
CZ - Repubblica Ceca 3
IN - India 3
JO - Giordania 3
BE - Belgio 2
HK - Hong Kong 2
TG - Togo 2
AT - Austria 1
PH - Filippine 1
Totale 701
Città #
Singapore 139
Santa Clara 98
Boardman 34
Abidjan 23
Helsinki 22
Bologna 17
Chandler 15
Dublin 11
Jakarta 11
Lappeenranta 8
Munich 8
Ashburn 7
Monzuno 7
Amsterdam 5
Bern 5
Cesena 5
Falkenstein 5
Xi'an 5
Fuzhou 4
Los Angeles 4
Milan 4
Princeton 4
Ravenna 4
Rome 4
Amman 3
Bagnacavallo 3
Brno 3
Forlì 3
Fort Worth 3
Foshan 3
Guangzhou 3
Shanghai 3
Sofia 3
Southend 3
Springfield 3
Boydton 2
Brussels 2
Changsha 2
Des Moines 2
Fairfield 2
Garbagnate Milanese 2
Hangzhou 2
Hong Kong 2
Lomé 2
Moscow 2
Naples 2
Rimini 2
Saronno 2
Senago 2
Treviso 2
Turin 2
Wilmington 2
Wustrow 2
Wuxi 2
Yantai 2
Acton 1
Anyang 1
Bergamo 1
Berlin 1
Cambridge 1
Chongqing 1
Dongguan 1
Florence 1
Forest City 1
Frankfurt am Main 1
Genazzano 1
Giovinazzo 1
Jiyuan 1
London 1
Manila 1
Nuremberg 1
Prineville 1
Qingdao 1
San Diego 1
Shaoxing 1
Taranto 1
Vienna 1
Totale 544
Nome #
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives 78
Moving beyond parp inhibition: Current state and future perspectives in breast cancer 65
Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant (SNV) Single Cell Analysis 55
Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure 36
An Italian Real-World Study Highlights the Importance of Some Clinicopathological Characteristics Useful in Identifying Metastatic Breast Cancer Patients Resistant to CDK4/6 Inhibitors and Hormone Therapy 32
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study 31
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 29
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience 28
Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology 27
Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer 26
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial. 25
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer 25
Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer 24
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): Pilot study with 18F-Fluoroestradiol (18F-FES) CT/PET 24
Real-world experience and clinical impact of drug-drug interactions in HR+/HER2- advanced breast cancer patients treated with abemaciclib plus endocrine therapy: the AB-ITALY study 23
Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment 20
Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab 19
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer? 18
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 18
Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer 18
Immunotherapy: The end of the "dark age" for metastatic triple-negative breast cancer? 18
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives 17
Atezolizumab plus Nab-paclitaxel in PD-L1–Positive TNBC—Letter 16
Eribulin in brain metastases of breast cancer: outcomes of the EBRAIM prospective observational trial 14
Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough? 12
The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer 12
Germline BRCA-mutated metastatic breast cancer with positive hormone receptor 11
Are we ready to use TMB in breast cancer clinical practice? 10
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 10
ANTIANGIOGENIC AGENTS ARE INEFFECTIVE TO INCREASE COMPLETE RESPONSE RATE IN MRCC. A META-ANALYSIS 6
Ribociclib and endocrine therapy in breast cancer 5
Precision medicine: PI3K targeting in advanced breast cancer 5
The promise of liquid biopsy in cancer: A clinical perspective 4
Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report 3
Totale 764
Categoria #
all - tutte 3.030
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.030


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202241 0 0 0 4 4 0 3 2 0 9 11 8
2022/202384 2 8 4 8 5 10 2 7 20 3 6 9
2023/2024134 1 3 0 2 1 4 6 4 67 19 17 10
2024/2025505 39 125 75 74 147 45 0 0 0 0 0 0
Totale 764